| 产品详情 |
| Edit |   |
|---|
| Product Name | Tofacitinib |
|---|
| Description | Purity ≥99% (HPLC, TLC). Tofacitinib is a novel Janus kinase 3 (JAK3) inhibitor. JAK3 is a critical cytoplasmic tyrosine kinase in the signaling pathways of multiple cytokines (interleukin (IL)-2, -7, -15 and -21) that are associated with various T cell functions Preclinical and clinical data strongly support that Tofacitinib, as an immunosuppressant, prevents organ transplant rejection and alleviates the symptoms of autoimmune diseases, such as rheumatoid arthritis (RA) and psoriasis. West, K. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr. Opin. Investig. Drugs 10: 491-504 (2009) Tofacitinib showed greater antiproliferative and pro-apoptotic activity against murine multipotent factor-dependent cell Patersen-erythropoietin receptor (FDCP-EpoR) cells harboring JAK2(V617F) compared with JAK2(WT). Manshouri, T., et al. The JAK kinase inhibitor CP-690,550 suppresses |
|---|
| Size | 25mg, 50mg, 100mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | (3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-1-piperidinepropanenitrile; 1-(Cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-3-piperidinamine; CP 690550; Tofacitinib |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | C7905-90 |
|---|
| Price | |
|---|
| Order / More Info | Tofacitinib from UNITED STATES BIOLOGICAL |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|